Cabaletta Bio Fortifies Autoimmune Mission with $150 Million Capital Infusion

PHILADELPHIA, PA – May 04, 2026 – Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company developing targeted cell therapies for autoimmune diseases, today announced the pricing of a substantial $150 million underwritten public offering. The financing, which involves the sale of 51,725,000 shares of common stock at $2.90 per share, drew significant participation from a syndicate of high-profile investors, including pharmaceutical giant Eli Lilly and Company, and prominent life sciences funds like Bain Capital Life Sciences, Adage Capital Management, and Cormorant Asset Management.

This capital raise marks a pivotal moment for the Philadelphia-based company, providing a critical injection of funds to propel its ambitious clinical programs forward. The offering is expected to close around May 5, 2026, and will equip Cabaletta to accelerate the development of its lead candidate, rese-cel, which aims to offer a potentially curative treatment for patients grappling with a range of debilitating autoimmune conditions.

Fueling the Clinical Engine

The roughly $150 million in gross proceeds dramatically extends Cabaletta Bio’s financial runway, a crucial metric for any clinical-stage biotech. Based on the company's most recent financial filings, it held approximately $163.6 million in cash and investments prior to this offering. With a reported net cash burn of about $168 million in 2025, its previous cash reserves were projected to last into the fourth quarter of 2026.

This new financing effectively de-risks the company’s near-term financial standing. The influx of capital boosts Cabaletta's pro forma cash position to over $313 million, extending its operational runway well into late 2027 or early 2028. This extended timeline provides the stability needed to execute on key clinical milestones without the immediate pressure of seeking additional funding. It allows the company to focus on advancing its lead programs through critical late-stage trials, a phase where costs typically escalate significantly.

A Vote of Confidence from Industry Giants

The composition of the investor group is as significant as the amount raised. The participation of Eli Lilly and Company is a powerful endorsement, signaling strategic interest from one of the world's largest pharmaceutical firms. For Lilly, which has been actively expanding its immunology portfolio, the investment represents a strategic foothold in the burgeoning field of autoimmune cell therapy. It suggests a strong belief in the scientific validity of Cabaletta's approach and could pave the way for future collaborations or partnerships.

Similarly, the involvement of dedicated funds like Bain Capital Life Sciences, Adage Capital Management, and Cormorant Asset Management underscores deep-seated confidence from investors who specialize in the biotech sector. These firms are known for conducting rigorous due diligence, and their investment serves as a strong validation of Cabaletta's CABA™ platform, its clinical strategy, and its management team. The presence of new mutual and sovereign wealth funds also indicates a broadening recognition of the long-term potential of cell therapies to revolutionize the treatment of autoimmune diseases.

Rese-cel: A Potential Paradigm Shift for Patients

At the heart of this investor confidence is Cabaletta's lead candidate, rese-cel. It is a type of Chimeric Antigen Receptor T cell (CAR T) therapy—a technology that has already transformed cancer treatment—engineered specifically for autoimmunity. Rese-cel is designed to target and eliminate CD19-expressing B cells, which play a central role in driving the pathology of many autoimmune diseases. The goal is to reset the immune system and induce a deep, durable, and potentially curative remission without the need for chronic immunosuppressive drugs.

Rese-cel is currently being evaluated in the company's RESET™ clinical development program across a range of diseases with high unmet needs, including myositis, systemic sclerosis, lupus, and myasthenia gravis. Recent clinical data presented in late 2025 has been promising, with reports of transformative, drug-free responses and a favorable safety profile that could support outpatient administration—a key advantage over more intensive cell therapy regimens.

Key upcoming milestones are now well-funded. The company is advancing a registrational cohort for rese-cel in myositis, a severe muscle-wasting disease, and has already received PRIME, RMAT, and Fast Track designations from European and U.S. regulators to expedite its development. A Biologics License Application (BLA) submission for this indication is targeted for 2027. Furthermore, crucial data from a cohort of lupus patients treated with rese-cel without any preconditioning chemotherapy is expected in the first half of 2026, which could represent a major step forward in improving the safety and accessibility of cell therapy.

Navigating a Competitive and Costly Landscape

While the outlook is promising, Cabaletta is not operating in a vacuum. The field of autoimmune cell therapy is becoming increasingly competitive, with other agile biotechs like Kyverna Therapeutics and large pharmaceutical players such as Novartis and Gilead's Kite Pharma also exploring the space. Differentiating its platform will be critical for success.

Cabaletta aims to stand out through its targeted clinical strategy and its focus on developing a less toxic, preconditioning-free regimen. Another significant hurdle for all cell therapy developers is manufacturing cost and complexity. Autologous CAR T therapies, which are made from a patient's own cells, are notoriously expensive to produce. To address this, Cabaletta is working to implement an automated manufacturing process with its Cellares platform, which it expects to bring online clinically in 2026. This technology has the potential to significantly reduce costs and scale production to meet future demand.

Analysts have largely reacted positively to the company's strategy and progress, with a consensus "Buy" rating and price targets suggesting significant upside. The new capital, combined with strong investor backing and promising clinical data, places Cabaletta at a crucial juncture. The journey to commercialization in a competitive landscape remains challenging, but the company is now better equipped than ever to pursue its goal of delivering potentially curative therapies to patients in need.